News
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Is Accenture (ACN) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Solventum (SOLV) Recently Broke Out Above the 200-Day Moving Average
Solventum (SOLV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, SOLV broke through the 200-day moving average, which suggests a
Compared to Estimates, Under Armour (UAA) Q4 Earnings: A Look at Key Metrics
For the quarter ended March 2026, Under Armour (UAA) reported revenue of $1.17 billion, down 0.8% over the same period last year. EPS came in at -$0.03, compared to -$0.08 in the year-ago quarter.
Earnings Growth & Price Strength Make Block (XYZ) a Stock to Watch
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
One of our most popular
Is DXP Enterprises (DXPE) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm
Aramark (ARMK) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
For the quarter ended March 2026, Aramark (ARMK) reported revenue of $4.91 billion, up 14.7% over the same period last year. EPS came in at $0.49, compared to $0.34 in the year-ago quarter.
The
Sleep Number (SNBR) Reports Q1 Loss, Beats Revenue Estimates
Sleep Number (SNBR) came out with a quarterly loss of $2.19 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.38 per share a year ago. These figures are
Why Micron (MU) is a Top Stock for the Long-Term
Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.
The Zacks Premium
QBTS Q1 Earnings Top Estimates, Revenues Miss, Stock Up
D-Wave Quantum Inc. QBTS posted a first-quarter 2026 loss of 5 cents per share, narrower than the Zacks Consensus Estimate of a loss of 8 cents. The reported figure widened from a loss of 2 cents in
Company News for May 12, 2026
- Barrick Mining Corporation’s B shares jumped 9% after reporting first-quarter 2026 adjusted earnings of 98 cents per share, beating the Zacks Consensus Estimate of 74 cents.
- Shares of Kodiak Gas
Stock Market News for May 12, 2026
Wall Street closed slightly higher on Monday, driven by energy and industrial stocks. Investors continued buying technology and AI-linked stocks even as inflation-related concerns remained regarding
Lincoln Educational Services Corporation (LINC) Hit a 52 Week High, Can the Run Continue?
Have you been paying attention to shares of Lincoln Educational Services Corporation (LINC)? Shares have been on the move with the stock up 24.1% over the past month. The stock hit a new 52-week
Why SkinHealth Systems Inc. (SKIN) International Revenue Trends Deserve Your Attention
Have you evaluated the performance of SkinHealth Systems Inc.'s (SKIN) international operations for the quarter ending March 2026? Given the extensive global presence of this company, analyzing the
Don't Overlook M/A-Com (MTSI) International Revenue Trends While Assessing the Stock
Have you looked into how M/A-Com (MTSI) performed internationally during the quarter ending March 2026? Considering the widespread global presence of this chipmaker, examining the trends in
Monster Beverage (MNST) International Revenue Performance Explored
Have you evaluated the performance of Monster Beverage's (MNST) international operations for the quarter ending March 2026? Given the extensive global presence of this energy drink maker, analyzing
Curious about Canadian Solar (CSIQ) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Analysts on Wall Street project that Canadian Solar (CSIQ) will announce quarterly loss of -$1.08 per share in its forthcoming report, representing a decline of 0.9% year over year. Revenues are
OrganiGram (OGI) Reports Q2 Loss, Misses Revenue Estimates
OrganiGram (OGI) came out with a quarterly loss of $0.01 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.05 per share a year ago. These figures are adjusted for
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
Believe it or not, seniors fear running out of cash more than they fear dying.
And unfortunately, even retirees who have built a nest egg have good reason to be concerned-with the traditional
Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks
Here's a revealing data point: older Americans are scared more of outliving wealth than of death itself.
Also, retirees who have constructed a nest egg have valid justifications to be concerned
Fastly's Q1 Revenues Rise 20%: Can Growth Stay Near Record Highs?
Fastly, Inc. FSLY entered 2026 with strong momentum, as first-quarter revenues increased 20% year over year to a record $173 million. Rising demand across edge cloud, security and compute services
Celsius Says Energy Drink Demand Still Strong as Shelf Reset Weighs on Growth
Celsius (NASDAQ:CELH) executives said the energy drink category remains stronger than expected, while the company is working through a temporary timing gap
Pangaea Logistics Solutions Q1 Earnings Call Highlights
Pangaea Logistics Solutions (NASDAQ:PANL) reported a stronger start to 2026, with management pointing to higher shipping activity, firmer dry bulk market conditions and continued benefits from its
Organigram Global Q2 Earnings Call Highlights
Organigram Global (NASDAQ:OGI) reported a weaker second quarter for fiscal 2026, with management attributing the decline to operational issues
Legend Biotech Q1 Earnings Call Highlights
Legend Biotech (NASDAQ:LEGN) reported sharply higher first-quarter 2026 sales for CARVYKTI, its CAR T therapy for multiple myeloma, as management said demand


